Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab Long-Term Safety and Efficacy Study (WAVE)
NCT04078152Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2019
- Primary completion
- Oct 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 31
01
Overview
A Phase 4 trial of durvalumab in solid tumor, sponsored by AstraZeneca. Started Sep 2019; status: completed.
02
Drugs
durvalumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04078152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04078152.